Publications & Presentations

DateTitle
August 9, 2018
Download Documentation Corporate Presentation - Canaccord Growth Conference 2018
August 2, 2018
Download Documentation CG-806, First-in-Class Pan-FLT3 / Pan-BTK Inhibitor, Demonstrates Superiority to Other FLT3 and BTK Inhibitors Against Primary Patient Samples
July 9, 2018
Download Documentation Corporate Presentation - July 2018
June 15, 2018
Download Documentation 2018 EHA Poster - CG-806, a Non Covalent Pan-FLT3/Pan-BTK Inhibitor, Exhibits Unique Binding to Wild Type and C481S Mutant BTK and Greater Potency Than Ibrutinib Against Malignant B Cells
June 6, 2018
Download Documentation Corporate Presentation - June 2018
April 17, 2018
Download Documentation APTO-253 is a new addition to the repertoire of drugs that can exploit DNA BRCA1/2 deficiency
April 15, 2018
Download Documentation 2018 AACR Poster - CG’806, a first-in-class pan-FLT3/pan-BTK inhibitor, demonstrates superiority to other FLT3 and BTK inhibitors against primary patient samples
April 15, 2018
Download Documentation 2018 AACR Poster - CG’806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro
December 11, 2017
Download Documentation 2017 ASH Poster - CG’806, a Novel Pan-FLT3/BTK Multi-Kinase Inhibitor, Induces Cell Cycle Arrest, Apoptosis or Autophagy in AML Cells Depending on FLT3 Mutational Status
December 11, 2017
Download Documentation 2017 ASH Poster - CG’806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition as a Single Agent and in Combination with a BET Bromodomain Inhibitor and a Bcl2 Inhibitor Against AML and CLL Patient Samples
December 10, 2017
Download Documentation 2017 ASH Poster - The Pan-FLT3/BTK Multi-Kinase Inhibitor CG’806 Induces AML Killing in FLT-Mutant and Wild Type Cells, and Exerts Synergistic Pro-Apoptotic Effects with Concomitant Targeting of Anti-Apoptotic Bcl-2 and/or Mcl-1
August 25, 2017
Download Documentation Q2 2017 Earnings Transcript
June 6, 2017
Download Documentation Annual Shareholders Meeting Presentation
May 7, 2017
Download Documentation CG’806, a First-in-Class FLT3/BTK Inhibitor, Exhibits Potent Activity Against AML
May 7, 2017
Download Documentation CG’806, a First‐in‐Class FLT3/BTK Inhibitor, Exerts Superior Potency Against AML Cells Harboring FLT3‐ITD, TKD, and Gatekeeper Mutant or Wild‐Type FLT3
December 3, 2016
Download Documentation ASH Poster
December 6, 2015
Download Documentation ASH Poster 2015
December 5, 2015
Download Documentation Broad Activity of APTO-253 in AML and Other Hematologic Malignancies Correlates with KLF4 Expression Level
May 8, 2014
Download Documentation 2014 ASH Preclinical Update Poster
May 1, 2014
Download Documentation 2014 AACR Poster
May 2, 2013
Download Documentation 2013 AACR PD Studies
May 1, 2013
Download Documentation 2013 EEC ESMO Phase I Poster
May 1, 2013
Download Documentation 2012 AACR Tumor Immunology Conference
May 1, 2012
Download Documentation 2012 AACR Poster Combination Studies
Get help downloading or viewing the above file types